Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators

Shares of Mirati Therapeutics Inc.
MRTX,
-8.22%
were down 4.7% premarket on Friday after the company said the European Medicines Agency had issued a negative opinion on a marketing application for Krazati, a treatment for non-small cell lung cancer. “Mirati disagrees with the opinion and intends to request a formal re-examination,” the company said in a release Friday. The U.S. Food and Drug Administration in December granted accelerated approval to Krazati for KRAS-mutated locally advanced or metastatic non-small cell lung cancer. Mirati stock is down 25% in the year to date, while the S&P 500
SPX,
+0.20%
has gained 18%.